Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845712 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
A Phase 2 study of Thymidine Kinase 2 Deficiency, sponsored by UCB Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 8
- Study locations
NCT03845712: Active Phase 2 study of Thymidine Kinase 2 Deficiency, sponsored by UCB Biosciences.
NCT03845712 is a Phase 2 study of Thymidine Kinase 2 Deficiency that is active but no longer recruiting, run by UCB Biosciences. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03845712, a Phase 2 study of Thymidine Kinase 2 Deficiency, is active but no longer recruiting, sponsored by UCB Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.
Primary Outcome
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
Conditions Studied
Interventions
- DRUG doxecitine and doxribtimine
Study Locations (8)
Other
- Tk0102 4038 - Haifa
- Tk0102 4039 - Holon
- Tk0102 4037 - Nehariya
- Tk0102 3102 - Barcelona
- Tk0102 3121 - Esplugues de Llobregat
- Tk0102 3031 - Madrid
- Tk0102 3101 - Seville
New York
- Tk0102 1005 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-07-05 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03845712 still lists
NCT03845712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Thymidine Kinase 2 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which doxecitine and doxribtimine is the first listed.
NCT03845712 lists 8 locations in 2 states (Other, New York).
Frequently Asked Questions
What is clinical trial NCT03845712 about?
NCT03845712 is a clinical study titled "An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency". This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and ...
What is the current status of trial NCT03845712?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2019-07-05. Estimated completion is 2026-06-30.
What conditions does trial NCT03845712 study?
This clinical trial studies the following conditions: Thymidine Kinase 2 Deficiency.
What interventions are being tested in trial NCT03845712?
The interventions under investigation include: doxecitine and doxribtimine (DRUG).
Who is sponsoring clinical trial NCT03845712?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03845712 being conducted?
This trial has 8 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thymidine Kinase 2 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03845712's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI